Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism
Rabella Figueras, Mireia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Grasa, Eva (Institut d'Investigació Biomèdica Sant Pau)
Corripio, Iluminada (Institut d'Investigació Biomèdica Sant Pau)
Romero, Sergio (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Mañanas, Miquel Àngel (Universitat Politècnica de Catalunya. Escola Tècnica Superior d'Enginyeria Industrial de Barcelona)
Antonijoan Arbós, Rosa Ma (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Münte, Thomas F. (Institute of Psychology II, University of Lübeck, Germany)
Pérez Solà, Víctor (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Riba, Jordi (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Universitat Autònoma de Barcelona

Data:	2016
Resum:	Schizotypal personality disorder (SPD) is a schizophrenia-spectrum disorder characterized by odd or bizarre behavior, strange speech, magical thinking, unusual perceptual experiences, and social anhedonia. Schizophrenia proper has been associated with anomalies in dopaminergic neurotransmission and deficits in neurophysiological markers of self-monitoring, such as low amplitude in cognitive event-related brain potentials (ERPs) like the error-related negativity (ERN), and the error positivity (Pe). These components occur after performance errors, rely on adequate fronto-striatal function, and are sensitive to dopaminergic modulation. Here we postulated that analogous to observations in schizophrenia, SPD individuals would show deficits in self-monitoring, as measured by the ERN and the Pe. We also assessed the capacity of dopaminergic antagonists to reverse these postulated deficits. We recorded the electroencephalogram (EEG) from 9 SPD individuals and 12 healthy controls in two separate experimental sessions while they performed the Eriksen Flanker Task, a classical task recruiting behavioral monitoring. Participants received a placebo or 1 mg risperidone according to a double-blind randomized design. After placebo, SPD individuals showed slower reaction times to hits, longer correction times following errors and reduced ERN and Pe amplitudes. While risperidone impaired performance and decreased ERN and Pe in the control group, it led to behavioral improvements and ERN amplitude increases in the SPD individuals. These results indicate that SPD individuals show deficits in self-monitoring analogous to those in schizophrenia. These deficits can be evidenced by neurophysiological measures, suggest a dopaminergic imbalance, and can be reverted by dopaminergic antagonists.
Nota:	Altres ajuts: This study was funded by "Fundació La Marató de TV3", grant number: 0113310. The funding source had no role in study design, data collection and analysis, interpretation of results and preparation of the manuscript.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Schizotypal personality disorder ; Behavioral monitoring ; Neurophysiology ; Error-related negativity ; Dopaminergic antagonism
Publicat a:	NeuroImage. Clinical, Vol. 11 (june 2016) , p. 770-779, ISSN 2213-1582

DOI: 10.1016/j.nicl.2016.05.019
PMID: 27330977

10 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats